Key issues in the clinical development and implementation of TB vaccines in South Africa

Area of Science:

• Vaccinology
• Immunology
• Public Health

Background:

• Advancements in TB vaccine development are ongoing, with candidates in late-stage trials.
• Progress is hindered by a lack of understanding regarding protective immune responses and inadequate preclinical predictive models.
• Current vaccine candidates require large-scale clinical trials for efficacy evaluation.

Purpose of the Study:

• To identify critical gaps and challenges in the development and introduction of new tuberculosis vaccines.
• To propose solutions for overcoming these obstacles and facilitating efficient vaccine deployment.
• To inform policy and implementation strategies for a new TB vaccine.

Main Methods:

• Review of current TB vaccine development pipeline and challenges.
• Analysis of preclinical and clinical evaluation limitations.
• Consideration of implementation strategies and economic factors.

Main Results:

• Incomplete understanding of protective immunity and limited predictive animal models impede early-stage efficacy assessment.
• Technical difficulties in defining TB incidence and standardizing endpoints complicate large-scale clinical trials.
• Significant trial infrastructure and economic analyses are crucial for vaccine introduction.

Conclusions:

• Addressing knowledge gaps in immunology and improving preclinical models are essential for reliable vaccine development.
• Standardizing clinical trial endpoints and bolstering trial infrastructure are necessary for regulatory approval.
• Economic evaluations will guide policy decisions for the effective implementation of new TB vaccines.